CHEMBIO DIAGNOSTICS, INC. (NASDAQ:CEMI) Files An 8-K Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits.

Exhibits.

99.1 Press release dated February 8, 2018.

CHEMBIO DIAGNOSTICS, INC. Exhibit
EX-99.1 2 tv485262_ex99-1.htm EXHIBIT 99.1   Exhibit 99.1             Chembio Diagnostics Announces Proposed Public Offering of Common Shares   MEDFORD,…
To view the full exhibit click here

About CHEMBIO DIAGNOSTICS, INC. (NASDAQ:CEMI)

Chembio Diagnostics, Inc. (Chembio), and its subsidiary, Chembio Diagnostic Systems, Inc., develop, manufacture, market and license rapid point-of-care diagnostic tests (POCTs) that detect infectious diseases. The Company’s products available are rapid tests for the detection of human immunodeficiency virus (HIV) 1/2 antibodies, and a multiplex rapid test for the detection of HIV and Syphilis antibodies. The HIV 1/2 rapid tests employ in-licensed and lateral flow technologies that are used with all blood matrices as samples, and are manufactured in a standard cassette format, a dipstick format and a barrel format. Its HIV 1/2 rapid antibody detection test incorporates the Dual Path Platform (DPP) POCT technology. The DPP HIV 1/2 Assay detects antibodies to HIV 1 and 2 in oral fluid samples, as well as in all blood matrices. The Company’s product pipeline includes a multiplex rapid test for earlier detection of HIV and a multiplex test that detects HIV and Syphilis specific antibodies.